Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advancing clinical response against glioblastoma: Evaluating SHP1705 CRY2 activator efficacy in preclinical models and safety in phase I trials

1 Apr 2025

Abstract excerpt

BACKGROUND: It has been reported that circadian clock components, Brain and Muscle ARNT-Like 1 (BMAL1) and Circadian Locomotor Output Cycles Kaput (CLOCK), are essential for glioblastoma (GBM) stem cell (GSC) biology and survival. Consequently, we developed a novel Cryptochrome (CRY) activator SHP1705, which inhibits BMAL1-CLOCK transcriptional activity. METHODS: We utilized GlioVis to determine which circadian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Circadian rhythm and melatonin
Share to Reproductive Biology and Fertility

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40168112
DOI: 10.1093/neuonc/noaf089

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advancing clinical response against glioblastoma: Evaluating SHP1705 CRY2 activator efficacy in preclinical models and safety in phase I trialsPMID 40168112Read ↗

Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I TrialsSemantic proximity Read ↗

PER2 integrates circadian disruption and pituitary tumorigenesisSemantic proximity Read ↗

Circadian regulation of <i>MGMT</i> expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastomaSemantic proximity Read ↗

Circadian Gene <em>cry</em> Controls Glioblastoma Tumorigenesis through Modulation of <em>myc</em> ExpressionSemantic proximity Read ↗

Targeting circadian transcriptional programs through a cis-regulatory mechanism in triple negative breast cancerSemantic proximity Read ↗

Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the hostSemantic proximity Read ↗

Circadian Regulator CLOCK Recruits Immune-Suppressive Microglia into the GBM Tumor MicroenvironmentSemantic proximity Read ↗

Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulationSemantic proximity Read ↗

Development and Characterization of Triazole-Based WDR5 Inhibitors for the Treatment of GlioblastomaSemantic proximity Read ↗

Differential expression of the circadian clock network correlates with tumour progression in gliomas.Semantic proximity Read ↗

Timing gone awry: distinct tumour suppressive and oncogenic roles of the circadian clock and crosstalk with hypoxia signalling in diverse malignanciesSemantic proximity Read ↗

PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.